BML-260

BML-260 is a potent inhibitor of dual-specific phosphatases JSP-1 and DUSP22. BML-260 can activate UCP1 and thermogenesis in adipocytes in a JSP-1-independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB, STAT3, and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity[1][2].

Product Specifications

CAS Number

[101439-76-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

PPAR; STAT

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bml-260.html

Purity

99.65

Solubility

DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)C1=CC=C(N(C/2=O)C(SC2=C\C3=CC=CC=C3)=S)C=C1

Molecular Formula

C17H11NO3S2

Molecular Weight

341.40

Precautions

H302, H315, H319

References & Citations

[1]Williams D R, et al. Targeting phosphatase DUSP22 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression[J]. bioRxiv, 2024: 2024.04. 08.588643.|[2]Feng Z, et al. Identification of a rhodanine derivative BML-260 as a potent stimulator of UCP1 expression[J]. Theranostics, 2019, 9 (12) : 3501.